tag:blogger.com,1999:blog-7857054149675424609.post3455142924469182660..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: Clinical Trial Update for Solid Cancer Candidate Atu-027 Highly EncouragingDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger6125tag:blogger.com,1999:blog-7857054149675424609.post-2930223615252344642011-02-18T19:49:39.651+00:002011-02-18T19:49:39.651+00:00On whether Atu-027 involved some immuno-modulating...On whether Atu-027 involved some immuno-modulating pre-treatment: As far as I am aware, not. In fact, on page 14 they make a big deal around the fact that Atu027 did not require any pre-medication (hint, hint...). <br /><br />RE Benitec '099 re-issuance: I had already blogged about it a few months ago: http://rnaitherapeutics.blogspot.com/2010/09/beniteccsiro-win-major-patent-battle-in.html<Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-5077239694515854192011-02-17T23:31:50.595+00:002011-02-17T23:31:50.595+00:00Will you post on the US finalisation of the Graham...Will you post on the US finalisation of the Graham ‘099 Patent Re-Examination Certificate for Benitec yesterday and it's implications for RNAi companies?Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-23481900259025727692011-02-17T22:06:07.156+00:002011-02-17T22:06:07.156+00:00Dirk,
Do you know if Atu-027 was dosed with any a...Dirk,<br /><br />Do you know if Atu-027 was dosed with any accompanying immune-modulating treatment, such as dexamethasone?<br /><br />It seems unlikely that it would be tolerated so well without some sort of additional agents to help mitigate the complement cascades that tend to result from these types of charged particles.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-35982632988889055402011-02-16T13:13:59.001+00:002011-02-16T13:13:59.001+00:00RE the immune stimulation issue:
That's certa...RE the immune stimulation issue:<br /><br />That's certainly a fair question, but based on the presentation, cytokine activation was looked for, but not detected. This is corroborated by the pre-clinical studies conducted with Atu-027. These were some of the more rigorous studies in the field to rule out interferon-related off-target anti-cancer efficacy, something also acknowledged by Dr. Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-14578820055910909402011-02-16T11:46:05.174+00:002011-02-16T11:46:05.174+00:00Dirk,
I have a question regarding the Silence ther...Dirk,<br />I have a question regarding the Silence therapeutics presentation you've commented on. <br />Are you able to extract from the information they've provided anything that would indicate that ATU027 is silencing within the target cells, or could the reported tumour response be down to an immune system response?<br />Just thinking back to Alnylams recent release of data from their Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-9875495213082660772011-02-15T02:30:55.844+00:002011-02-15T02:30:55.844+00:00Dirk,
thank you for your comment about Marina'...Dirk,<br />thank you for your comment about Marina's style of financing. I am a burnt Marina/MDRNA investor and totally appalled at their recent financing. Yes I understand that they desperately needed cash. But that is because they are oversized. Their cash burn is just not justified by their science.Anonymousnoreply@blogger.com